The Proactive Molecular Risk Classifier for Endometrial cancer (ProMisE) was developed and validated as a clinically applicable surrogate molecular classifier8, 9, 10, 11, rendering four corresponding prognostic subgroups: POLE exonuclease domain mutations (POLE EDM), mismatch repair proteins deficiency (MMR‐D), protein 53 wild type (p53 wt) and protein 53 abnormal (p53 abn). Here, TP53 is linked to endometrial cancer.